FORMULATION AND EVALUATION OF GASTRORETENTIVE DELIVERY OF TIZANIDINE HYDROCHLORIDE USING NATURAL POLYMERS
HTML Full TextReceived on 03 November, 2013; received in revised form, 03 January, 2014; accepted, 16 March, 2014; published 01 April, 2014
FORMULATION AND EVALUATION OF GASTRORETENTIVE DELIVERY OF TIZANIDINE HYDROCHLORIDE USING NATURAL POLYMERS
Harshita Boorlagadda*, V. Sandeep, A. Madhusudan Reddy and P. Srinivasa Babu
Vignan Pharmacy College, Guntur, Andhra Pradesh, India
ABSTRACT: The present investigation concerns the design and evaluation of floating tablets of Tizanidine hydrochloride, which after oral administration are designed to prolong the gastric residence time and increased drug bioavailability. It is a centrally acting α2 adrenergic agonist. It is used in the treatment of migraine headaches, spasms and anticonvulsant. The dosage was designed by using natural polymers, Guar gum, Xanthan gum, Karaya gum, Psyllium and HPMC. Floating tablets prepared by direct compression technique. The prepared floating tablets were evaluated in terms of their precompression parameters, friability, hardness, uniformity of weight, drug content, swelling index, in-vitro dissolution studies. The floating properties and drug release studies were determined using 0.1N HCl as a dissolution medium. The best formulation was determined based on the buoyancy and drug release parameters.
Keywords: |
Tizanidine hydrochloride, HMPC, invitro drug release, buoyancy
INTRODUCTION:Tremendous advances have been seen in oral controlled drug delivery systems in the last two decades. In the development of oral controlled drug delivery system, one of the main challenges is to modify the GI transit time. Gastric emptying of pharmaceuticals is highly variable and is dependent on the dosage form and the fed/fasted state of the stomach. Normal gastric residence times usually range between 5 minutes and 2 hours. Drugs having a short half-life are eliminated quickly from the blood circulation. Various oral controlled delivery systems like gastro retention dosage forms have been designed to overcome this problem and release the drug to maintain its plasma concentration for a longer period of time.
Tizanidine hydrochloride has low bioavailability of 3.5-4hrs. It needs daily dosage of 2mg for three times. In order to increase the bioavailability and decrease the dosing, we need to formulate it in the form of sustained drug delivery.
In all sustained deliveries, Gastroretentive drug delivery plays an important role. The present study focus on the development of floating tablets of Tizanidine hydrochloride using different polymer grades to achieve a sustained release for long time.
MATERIALS AND METHODS: Tizanidine hydrochloride, Guar gum, Karaya gum, Xanthan gum, Psyllium are obtained from Sipra Labs limited, Hyderabad
Methods: Different formulations were prepared by direct compression technique. All the ingredients were passed through the sieve and placed in a polybag and mixed thoroughly. Magnesium stearate and talc were added later, and citric acid was added before tablet punching. The composition of all the formulations was shown in the Table 1.
TABLE 1: COMPOSITION OF DIFFERENT FORMULATIONS OF TIZANIDINE HCL
S. No. | T1 | T2 | T3 | T4 | T5 | T6 | T7 | T8 | T9 | T10 | T11 | T12 |
Tizanidine hydrochloride | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
HPMC K4M | 10 | 20 | 10 | 20 | ||||||||
Guar gum | 60 | 80 | 100 | |||||||||
Xanthan gum | 60 | 80 | 100 | |||||||||
Karaya gum | 60 | 80 | 100 | |||||||||
Psyllium | 60 | 80 | 100 | |||||||||
Calcium carbonate | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 |
Citric acid | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
MCC | 73 | 53 | 33 | 73 | 43 | 23 | 73 | 43 | 23 | 73 | 63 | 33 |
Magnesium stearate | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
Talc | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
Total | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 |
Evaluation Studies:
- Precompression Studies:
- Bulk Density (gm / ml): Apparent Bulk density (gm/ml) was determined by pouring gently about 5 gm of drugand excipients sample through a glass funnel into a 50 ml graduated measuring cylinder. Then after pouring the powder bed was made uniform without disturbing. Then the volume was measured directly from the graduation marks on the cylinder as ml. the volume measured was called as the bulk volume and the bulk density was calculated by following formula
Bulk density = Wight of the powder / Bulk volume
- Tapped Density (gm / ml): Tapped density was determined by pouring gently about 5 gm of drugand excipients sample through a glass funnel into a 50 ml graduated measuring cylinder. The cylinder was tapped from height of 2 inches until a constant volume was obtained. Volume occupied by the sample after tapping were recorded and tapped density was calculated by using following formula.
Tapped density = Weight of powder / Tapped volume
- Carr’s Compressibility Index (%): Compressibility is the ability of powder to decrease in volume under pressure. Compressibility is a measure that is obtained from density determinations. It is also one of the simple methods to evaluate flow property of powder by comparing the bulk density and tapped density.
Carr’s index = (Tapped density – Bulk density / Tapped density) × 100
- Hausner’s Ratio: Hausner’s ratio provides an indication of the degree of the densification which could resultfrom vibration of the feed hopper. A lower value indicates better flow and vice versa.
Hausner’s Ratio = Tapped density / Bulk density
- Angle of Repose:Angle of reposeis defined as the maximum angle possible between the surface of the pile of the powder and the horizontal plane. The flow characteristics of powder mixture were studied by measuring the angle of repose employing fixed funnel method.
Angle of repose (q ) = tan-1 (h / r)
The Precompression or Micromeretic parameters of all formulations were shown in the Table 2.
- Post compression parameters:
- Weight Variation: Formulated tablets were tested for weight uniformity, 20 tablets were weighed collectively and individually. From the collective weight, average weight was calculated. The percent weight variation was calculated by the following formula
% Weight variation = [(Average weight – Individual weight) / Average wt] × 100
The weight variation of all the formulations were shown in Table 3 8.
- Hardness: Hardness of the tablets was determined by using Monsanto hardness tester. The tablet to be tested is held in fixed and moving jaw and reading of the indicator adjusted to zero. Then force to the edge of the tablets was gradually increased by moving the screw knob forward until the tablet breaks. The reading was noted from the scale which indicates the pressure required in kg to break the tablet. The hardness of the tablets depends on the weight of the materials used, apace between the upper and lower punches at the time of compression and pressure applied during compression. The Hardness test of all the formulations were shown in Table 3 9.
- Friability: The Roche friability test apparatus was used to determine the friability of the tablets. Randomly selected twenty pre-weighed tablets were placed in the apparatus and operated for 100 revolutions and then the tablets were reweighed. The acceptable limits of the weight loss should not be more than 0.8%. The Friability of all the formulations was shown in Table 3. The percentage friability was calculated according to the following formula;
% Friability = [(Initial weight – Final weight) / Initial weight] × 100
- Floating lag time and Total floating time: Floating characteristics of the prepared formulations were determined using the 0.1N HCL. The tablets were placed in a 100ml beaker containing 0.1 N HCl at 37 ± 0.50 C. The time required for the tablet to rise to the surface and float on solution (Floating lag time) and the time during which dosage form remain buoyant on the solution (Total floating time) were measured 6. The Floating lag time and total floating time of all the formulations were shown in Table 4.
- Drug Content uniformity: Over ten tablets were selected randomly and average weight was calculated. Tablets were crushed in a mortar and accurately average weighed amount of tablets triturate was taken for analysis. The powder material was transferred in to a 100ml volumetric flask and it was diluted with the 0.1 N HCl. The content was shaken well and kept for 30 minutes for dissolving the drug. Then it was filtered and 1 ml of the filtrate was diluted to 10 ml using 0.1 N HCl to obtain 10 µg/ml solution then the absorbance was measured at 319nm 5. The Drug content uniformity of all the formulations was shown in Table 3.
- In-vitro Dissolution studies: In vitro drug release study of the samples was carried out by using USP – type II dissolution apparatus (Paddle type). The 0.1 N HCL was used as the dissolution medium. The 900ml of 0.1N HCl was placed into the dissolution flask maintaining the temperature of 37 ± 0.5oC and rpm of 50. 5 ml of sample was withdrawn after 0.5, 1, 2, 4, 6, 8, 10, and 12 hours and the same was replaced with fresh dissolution medium (37oC).
Collected samples were analyzed at 319nm using 0.1 N HCL as blank 6. The drug release experiments were conducted in triplicate. The in vitro drug release study was shown in Table 5 and in vitro drug release graph, Cumulative % drug released vs time for the formulations T1-T3 was shown in the Fig. 1 and T4-T6 was shown in the Fig. 2, T7-T9 was shown in the Fig. 3 and T10-T12 was shown in the Fig. 4 12.
RESULTS AND DISCUSSIONS:
- Precompression Evaluations:
TABLE 2: MICROMERETIC PROPERTIES OF FORMULATIONS T1-T12
Formulation | Bulk Density (gm/ml) | Tapped Density (gm/ml) | Compressibility Index (%) | Hausner’s Ratio | Angle of Repose |
T1 | 0.499 ±0.002 | 0.527±0.005 | 5.56 ±0.018 | 1.15 ±0.002 | 23.15 ±0.571 |
T2 | 0.456 ±0.007 | 0.531 ±0.008 | 7.89 ±0.021 | 1.06 ±0.001 | 22.67 ±0.448 |
T3 | 0.461 ±0.002 | 0.487 ±0.008 | 8.51 ±0.036 | 1.08 ±0.000 | 24.87 ±0.633 |
T4 | 0.485 ±0.001 | 0.522 ±0.009 | 7.56 ±0.045 | 1.13 ±0.002 | 29.79 ±0.522 |
T5 | 0.478 ±0.002 | 0.469 ±0.003 | 6.77 ±0.044 | 1.09 ±0.001 | 24.83 ±0.271 |
T6 | 0.505 ±0.003 | 0.495 ±0.003 | 8.96 ±0.025 | 1.10 ±0.002 | 23.19 ±0.444 |
T7 | 0.463 ±0.002 | 0.477 ±0.002 | 9.73 ±0.012 | 1.07 ±0.001 | 22.73 ±0.562 |
T8 | 0.472 ±0.003 | 0.515 ±0.004 | 7.56 ±0.081 | 1.10 ±0.000 | 27.85 ±0.456 |
T9 | 0.489 ±0.002 | 0.453 ±0.006 | 5.59 ±0.051 | 1.09 ±0.002 | 24.82 ±0.554 |
T10 | 0.502 ±0.001 | 0.483 ±0.007 | 6.99 ±0.058 | 1.04 ±0.000 | 25.34 ±0.436 |
T11 | 0.488 ±0.002 | 0.461 ±0.005 | 7.39 ±0.085 | 1.07 ±0.000 | 24.11 ±0.542 |
T12 | 0.492 ±0.003 | 0.514 ±0.006 | 8.55 ±0.067 | 1.12 ±0.002 | 33.77 ±0.473 |
- Post Compression Evaluation:
TABLE 3: PHYSICAL PROPERTIES OF FORMULATIONS T1-T12
S. No. | Weight Variation (mg) | Hardness (kg/ cm2) | Friability (%) | Drug Content (%) |
T1 | 199 | 3.8 | 0.58 | 99.08 |
T2 | 201 | 4.0 | 0.66 | 100.02 |
T3 | 198 | 4.5 | 0.75 | 98.36 |
T4 | 200 | 4.2 | 0.85 | 99.71 |
T5 | 199 | 4.3 | 0.53 | 100.02 |
T6 | 198 | 3.9 | 0.68 | 101.03 |
T7 | 200 | 4.0 | 0.79 | 99.73 |
T8 | 199 | 4.4 | 0.72 | 99.87 |
T9 | 200 | 3.9 | 0.59 | 99.89 |
T10 | 198 | 4.0 | 0.62 | 99.99 |
T11 | 198 | 4.2 | 0.72 | 100.07 |
T12 | 199 | 3.7 | 0.73 | 101.56 |
In-vitro Buoyancy:
TABLE 4: FLOATING LAG TIME AND TOTAL FLOATING TIME OF DESIGNED FORMULATIONS
S. No. | Floating Lag Time (sec) | Total Floating Time (hrs) |
T1 | 030 | >12 |
T2 | 029 | >12 |
T3 | 025 | >12 |
T4 | 040 | >12 |
T5 | 026 | >13 |
T6 | 020 | >13 |
T7 | 030 | >14 |
T8 | 029 | >15 |
T9 | 025 | >15 |
T10 | 026 | >12 |
T11 | 028 | >12 |
T12 | 029 | >12 |
In vitro Drug Release Study:
TABLE 5: DRUG RELEASE KINETIC DATA OF TIZANIDINE HYDROCHLORIDE WITH GUAR GUM, XANTHAN GUM, KARAYA GUM, PSYLLIUM
Formulation | Correlation coefficient | ||||
Zero order | First order | Higuchi | Peppas | Hixon Crowell | |
T1 | 0.711 | 0.971 | 0.929 | 0.390 | 0.917 |
T2 | 0.765 | 0.827 | 0.946 | 0.410 | 0.980 |
T3 | 0.759 | 0.923 | 0.968 | 0.448 | 0.943 |
T4 | 0.833 | 0.944 | 0.979 | 0.662 | 0.991 |
T5 | 0.989 | 0.956 | 0.987 | 0.639 | 0.986 |
T6 | 0.991 | 0.969 | 0.974 | 0.687 | 0.990 |
T7 | 0.962 | 0.988 | 0.995 | 0.627 | 0.992 |
T8 | 0.992 | 0.977 | 0.998 | 0.614 | 0.990 |
T9 | 0.991 | 0.987 | 0.996 | 0.616 | 0.991 |
T10 | 0.789 | 0.933 | 0.997 | 0.702 | 0.990 |
T11 | 0.885 | 0.953 | 0.995 | 0.626 | 0.991 |
T12 | 0.887 | 0.977 | 0.998 | 0.636 | 0.992 |
FIG. 1: IN VITRO DISSOLUTION PROFILE OF FORMULATION F1-F3
FIG. 2: IN VITRO DISSOLUTION PROFILE OF FORMULATION T4-T6
FIG. 3: IN VITRO DISSOLUTION PROFILE OF FORMULATION T7-T9
FIG. 4: IN VITRO DISSOLUTION PROFILE OF FORMULATION T10-T12
CONCLUSION: From the above studies, it was concluded that all the formulations designed with gas generating agents showed sustained release or zero order drug release. The formulations designed with natural polymer and small amounts of HPMC in case of Xanthan gum and Karaya gum showed better drug release than their the formulations without HPMC. From this study it was concluded that Tizanidine hydrochloride formulated with Karaya gum with HPMC showed gastric retention up to 16hrs. T9 is the best formulation among all designed formulations. The best formulated was concluded based on drug release and Total floating time.
REFERENCES:
- Arora S, Ali J, Ahuja A, Khar RK, Baboota S., “Floating drug delivery System: A Review”. AAPS Pharm Sci Tech, 372-390, 2005.
- Chaudhari Pravin, Chaudhari shilpa, Barhate Nilesh, Mistry Chetan and Kolsure Pramod, “Design and Evaluation of Bilayer Floating Tablets of Tizanidine Hydrochloride”, Indian J. of Pharm Education and research, 36-48 2007.
- S. P. Vyas and Roop. K. Khar, Controlled Drug Delivery Concepts and Advances, First edition 196-217, 2002.
- Anand. P. Gadad, Suma. N. Naduvinamani, M. B. Patil, V. S. Mastiholimath, P.M. Dandagi and F. V. Manvi, “Floating Alginate Beads: a novel approach to prolong gastric residence, an Overview”, Int J Pharma Excip, 5-10, 2008.
- Mr. Shinde Anilkumar J, “Gastro retentive Drug Delivery System: An Overview”, Pharmainfo.net, vol (6), 2008.
- Surrender Varma, Neha Narang, “Development and in vitro evaluation of Floating matrix tablets of Anti Retroviral drug”, International Journal of Pharmacy and Pharmaceutical Sciences, 3(1), 208-211, 2011.
- Pathak Naresh Shriram, “Formulation and in vitro evaluation of Floating microspheres of Lansoprazole”. Rajiv Ghandi University of health Sciences, 2011.
- Himansu Bhusan Samal, “Formulation characterization and in vitro evaluation of Floating microspheres of Nateglinide”, International Journal of Pharma and Bio Sciences, 2 (1), P-147_P-156, 2011.
- Adimoolam Senthil, Rahul Goroba Raut, Prashant sharad Salunke, Sonal Umesh Kulkarni, Narayana Swami VB, “Formulation and evaluation of Floating tablets of Tizanidine hydrochloride”, International Research Journal of Pharmacy, 2 (8), 124-129, 2011.
- R. K. Nayak, B.Manjunath, V.B.Narayana Swamy, A.Senthil1, H.K.Thakkar1, D. M. Kumar and R. Mahalaxmi: “Design and evaluation of sustained release Floating tablets of loratidine”, Asian Journal of Biochemical and Pharmaceutical Research, 1 (3), 105-124, 2011.
- Kulkarni Vishakha S*, Butte Kishor D and Rathod Sudha S Natural Polymers – A Comprehensive Review. International Journal of Research in Pharmaceutical and Biomedical Sciences ISSN: 2229-3701.
How to cite this article:
Boorlagadda H, Sandeep V, Reddy AM and Babu PS: Formulation and evaluation of Gastroretentive Delivery of Tizanidine hydrochloride using natural polymers. Int J Pharm Sci Res 2014; 5(4): 1533-38.doi: 10.13040/IJPSR.0975-8232.5(4).1533-38
All © 2013 are reserved by International Journal of Pharmaceutical Sciences and Research. This Journal licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.
Article Information
54
1533-1538
618KB
1432
English
IJPSR
https://ijpsr.com/wp-content/uploads/2014/09/54-Vol.-5-Issue-4-April-2014-IJPSR-RA-3230-Paper-54.pdf
Vignan Pharmacy College, Guntur, Andhra Pradesh, India
harshipharma@gmail.com
03 November, 2013
03 January, 2014
16 March, 2014
http://dx.doi.org/10.13040/IJPSR.0975-8232.5(4).1533-38
01 April, 2014